AAP
WX

Ardsley Advisory Partners’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Ardsley Advisory Partners’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-17,000
Closed -$652K – 298
2013
Q4 		$652K Buy
+17,000
New +$537K 0.09% 80

Other funds holding WX

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ardsley Advisory Partners's WX Position: Q1 2014 in Review

Ardsley Advisory Partners sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q1 2014, closing a stake of 17,000 shares — an estimated $652K sold.

Ardsley Advisory Partners first reported a position in WX in Q4 2013 and held it in 1 quarter. The position peaked at $652K in Q4 2013. 164 funds tracked by Wall St. Rank hold WX as of Q1 2014.

  • Ardsley Advisory Partners reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q1 2014 after selling out during the quarter.
  • Ardsley Advisory Partners sold 17,000 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q1 2014, an estimated $652K.
  • Ardsley Advisory Partners first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q4 2013 and held it in 1 quarter.
  • Ardsley Advisory Partners's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $652K in Q4 2013.
  • 164 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q1 2014.

Based on Ardsley Advisory Partners's 13F filing for Q1 2014, filed 15 May 2014.